TY - JOUR
T1 - Tumour p53 mutations exhibit promoter selective dominance over wild type p53
AU - Monti, Paola
AU - Campomenosi, Paola
AU - Ciribilli, Yari
AU - Iannone, Raffaella
AU - Inga, Alberto
AU - Abbondandolo, Angelo
AU - Resnick, Michael A.
AU - Fronza, Gilberto
PY - 2002/3/7
Y1 - 2002/3/7
N2 - The tumour suppressor gene p53 is frequently mutated in human cancer. Tumour derived p53 mutants are usually transcriptionally inactive, but some mutants retain the ability to transactivate a subset of p53 target genes. In addition to simple loss of function, some p53 mutants may be carcinogenic through a dominant negative mechanism. Aiming at a more general classification of p53 mutants into predictive functional categories it is important to determine (i) which p53 mutants are dominant, (ii) what features characterize dominant mutants and (iii) whether dominance is target gene specific. The ability of 71 p53 mutants to inhibit wild type p53 was determined using a simple yeast transcriptional assay. Approximately 30% of the mutants were dominant. They preferentially affect highly conserved amino acids (P
AB - The tumour suppressor gene p53 is frequently mutated in human cancer. Tumour derived p53 mutants are usually transcriptionally inactive, but some mutants retain the ability to transactivate a subset of p53 target genes. In addition to simple loss of function, some p53 mutants may be carcinogenic through a dominant negative mechanism. Aiming at a more general classification of p53 mutants into predictive functional categories it is important to determine (i) which p53 mutants are dominant, (ii) what features characterize dominant mutants and (iii) whether dominance is target gene specific. The ability of 71 p53 mutants to inhibit wild type p53 was determined using a simple yeast transcriptional assay. Approximately 30% of the mutants were dominant. They preferentially affect highly conserved amino acids (P
KW - Dominance
KW - Mutation
KW - p53
KW - p53 responsive element
KW - Yeast functional assay
UR - http://www.scopus.com/inward/record.url?scp=0037034946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037034946&partnerID=8YFLogxK
U2 - 10.1038/sj/onc/1205250
DO - 10.1038/sj/onc/1205250
M3 - Article
C2 - 11896595
VL - 21
SP - 1641
EP - 1648
JO - Oncogene
JF - Oncogene
SN - 0950-9232
IS - 11
ER -